Trevi Therapeutics, Inc. (TRVI) saw its stock price plummet 5.39% during intraday trading on Wednesday, following the release of its first-quarter financial results.
The company reported a Q1 loss of $0.09 per diluted share, which was unchanged from the same period a year earlier. However, this result missed the FactSet analyst consensus estimate, which had expected a loss of $0.08 per share.
The earnings disappointment appears to be the primary driver behind the stock's sharp decline in the session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments